UY29710A1 - Benzimidazoles tricíclicos y su uso como moduladores de receptores metabotrópicos de glutamato - Google Patents
Benzimidazoles tricíclicos y su uso como moduladores de receptores metabotrópicos de glutamatoInfo
- Publication number
- UY29710A1 UY29710A1 UY29710A UY29710A UY29710A1 UY 29710 A1 UY29710 A1 UY 29710A1 UY 29710 A UY29710 A UY 29710A UY 29710 A UY29710 A UY 29710A UY 29710 A1 UY29710 A1 UY 29710A1
- Authority
- UY
- Uruguay
- Prior art keywords
- benzimidazols
- tricyclic
- modulators
- metabotropic glutamate
- glutamate receptors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/06—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Abstract
Un compuesto de fórmula (I) o su sal aceptable para uso farmacéutico: en donde R1, R2, R3, A,B, D, m, n, x, e y tienen los valores que se describen en la memoria descriptiva. Una composición farmacéutica que comprende el compuesto de fórmula I, junto con un método de usarlo para tratar o prevenir trastornos neutológicos y psiquiátricos. Los compuestos son útiles en terapias relacionadas con el tratamiento o prevención de trastornos mediados por el receptor de mG1uR2.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US70547105P | 2005-08-05 | 2005-08-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY29710A1 true UY29710A1 (es) | 2007-02-28 |
Family
ID=37607094
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY29710A UY29710A1 (es) | 2005-08-05 | 2006-07-28 | Benzimidazoles tricíclicos y su uso como moduladores de receptores metabotrópicos de glutamato |
Country Status (17)
Country | Link |
---|---|
US (2) | US20080318999A1 (es) |
EP (1) | EP1912989A2 (es) |
JP (1) | JP2009503069A (es) |
KR (1) | KR20080035576A (es) |
CN (1) | CN101268077A (es) |
AR (1) | AR055100A1 (es) |
AU (1) | AU2006279034A1 (es) |
BR (1) | BRPI0614168A2 (es) |
CA (1) | CA2616020A1 (es) |
EC (1) | ECSP088128A (es) |
IL (1) | IL188809A0 (es) |
MX (1) | MX2008001152A (es) |
NO (1) | NO20080475L (es) |
RU (1) | RU2008101923A (es) |
TW (1) | TW200745112A (es) |
UY (1) | UY29710A1 (es) |
WO (1) | WO2007018998A2 (es) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE529246C2 (sv) * | 2005-10-13 | 2007-06-12 | Neurosearch Sweden Ab | Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission |
EP1963268B1 (en) * | 2005-12-07 | 2010-12-01 | NSAB, Filial af NeuroSearch Sweden AB, Sverige | Disubstituted phenylpiperidines as modulators of cortical catecholaminergic neurotransmission |
TWI417095B (zh) * | 2006-03-15 | 2013-12-01 | Janssen Pharmaceuticals Inc | 1,4-二取代之3-氰基-吡啶酮衍生物及其作為mGluR2-受體之正向異位性調節劑之用途 |
TW200845978A (en) * | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
EP2150244A1 (en) * | 2007-04-23 | 2010-02-10 | House Ear Institute | Treatment and/or prevention of presbycusis by modulation of metabotropic glutamate receptor 7 |
JP5433579B2 (ja) | 2007-09-14 | 2014-03-05 | ジャンセン ファーマシューティカルズ, インコーポレイテッド. | 1,3−二置換−4−フェニル−1h−ピリジン−2−オン |
TWI445532B (zh) | 2007-09-14 | 2014-07-21 | Janssen Pharmaceuticals Inc | 1’,3’-二取代-4-苯基-3,4,5,6-四氫-2h,1’h-〔1,4’〕聯吡啶基-2’-酮化物 |
TW200922566A (en) | 2007-09-14 | 2009-06-01 | Ortho Mcneil Janssen Pharm | 1,3 disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones |
ES2637794T3 (es) * | 2007-11-14 | 2017-10-17 | Janssen Pharmaceuticals, Inc. | Derivados de imidazo[1,2-A]piridina y su uso como moduladores alostéricos positivos de receptores MGLUR2 |
DE102008022221A1 (de) * | 2008-05-06 | 2009-11-12 | Universität des Saarlandes | Inhibitoren der humanen Aldosteronsynthase CYP11B2 |
CA2723727A1 (en) * | 2008-05-15 | 2009-11-19 | Merck Sharp & Dohme Corp. | Oxazolobenzimidazole derivatives |
AU2009246629A1 (en) * | 2008-05-15 | 2009-11-19 | Merck Sharp & Dohme Corp. | Oxazolobenzimidazole derivatives |
AU2009260469B2 (en) * | 2008-05-29 | 2014-02-13 | Albany Molecular Research, Inc. | 5-HT3 receptor modulators, methods of making, and use thereof |
EP2303019A4 (en) * | 2008-06-25 | 2013-07-17 | Bermans S Iskandar | (6S) -5-METHYLTETRAHYDROFOLIC ACID FOR THE TREATMENT OF TISSUE INJURIES |
CA2735764C (en) | 2008-09-02 | 2016-06-14 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors |
AU2009296931A1 (en) * | 2008-09-26 | 2010-04-01 | Merck Sharp & Dohme Corp. | Oxazolobenzimidazole derivatives |
ES2466341T3 (es) | 2008-10-16 | 2014-06-10 | Janssen Pharmaceuticals, Inc. | Derivados de indol y benzomorfolina como moduladores de receptores de glutamato metabotrópicos |
WO2010060589A1 (en) | 2008-11-28 | 2010-06-03 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors |
MX2011011964A (es) | 2009-05-12 | 2012-02-23 | Janssen Pharmaceuticals Inc | Derivados de 1,2,3-triazolo[4,3-a]piridina y su uso para el tratamiento o prevencion de trastornos neurologicos y psiquiatricos. |
SG176018A1 (en) | 2009-05-12 | 2011-12-29 | Janssen Pharmaceuticals Inc | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
US8541404B2 (en) * | 2009-11-09 | 2013-09-24 | Elexopharm Gmbh | Inhibitors of the human aldosterone synthase CYP11B2 |
ES2536433T3 (es) | 2010-11-08 | 2015-05-25 | Janssen Pharmaceuticals, Inc. | Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2 |
PL2649069T3 (pl) | 2010-11-08 | 2016-01-29 | Janssen Pharmaceuticals Inc | Pochodne 1,2,4-triazolo[4,3-a]pirydyny i ich zastosowanie jako dodatnich allosterycznych modulatorów receptorów mGluR2 |
JP5852666B2 (ja) | 2010-11-08 | 2016-02-03 | ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド | 1,2,4−トリアゾロ[4,3−a]ピリジン誘導体およびmGluR2受容体のポジティブアロステリックモジュレーターとしてのそれらの使用 |
WO2012112791A1 (en) | 2011-02-16 | 2012-08-23 | Paloma Pharmaceuticals, Inc. | Radiation countermeasure agents |
US9540343B2 (en) | 2011-07-06 | 2017-01-10 | Gilead Sciences, Inc. | Compounds for the treatment of HIV |
GB201220157D0 (en) * | 2012-11-08 | 2012-12-26 | Selvita Sa | Substitute tricyclic benzimidazoles as kinase inhibitors |
CN102964292A (zh) * | 2012-11-26 | 2013-03-13 | 盛世泰科生物医药技术(苏州)有限公司 | 4-(2-(三氟甲氧基)苯基)哌啶的合成 |
EP3581576B1 (en) * | 2013-03-15 | 2022-01-26 | Incyte Holdings Corporation | Tricyclic heterocycles as bet protein inhibitors for use in the treatment of a proliferative disease in combination with a janus kinase inhibitor |
JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
EP3019502B1 (en) | 2013-07-08 | 2017-05-17 | Incyte Holdings Corporation | Tricyclic heterocycles as bet protein inhibitors |
JO3367B1 (ar) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
KR101672096B1 (ko) * | 2013-09-30 | 2016-11-02 | 주식회사 엘지화학 | 헤테로환 화합물 및 이를 포함하는 유기 발광 소자 |
WO2015081189A1 (en) | 2013-11-26 | 2015-06-04 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
US9399640B2 (en) | 2013-11-26 | 2016-07-26 | Incyte Corporation | Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors |
US9309246B2 (en) | 2013-12-19 | 2016-04-12 | Incyte Corporation | Tricyclic heterocycles as BET protein inhibitors |
UA127921C2 (uk) | 2014-01-21 | 2024-02-14 | Янссен Фармацевтика Нв | Комбінації, які містять позитивні алостеричні модулятори або ортостеричні агоністи метаботропного глутаматергічного рецептора 2 підтипу, та їх застосування |
DK3096790T3 (da) | 2014-01-21 | 2019-10-07 | Janssen Pharmaceutica Nv | Kombinationer omfattende positive allosteriske modulatorer eller orthosteriske agonister af metabotrop glutamaterg subtype 2-receptor og anvendelse af disse |
US10202353B2 (en) | 2014-02-28 | 2019-02-12 | Gilead Sciences, Inc. | Therapeutic compounds |
WO2015154047A1 (en) * | 2014-04-03 | 2015-10-08 | Restorgenex Corporation | Novel methods |
CN106414442B (zh) | 2014-04-23 | 2019-03-15 | 因赛特公司 | 作为BET蛋白抑制剂的1H-吡咯并[2,3-c]吡啶-7(6H)-酮和吡唑并[3,4-c]吡啶-7(6H)-酮 |
EP3144311A4 (en) | 2014-05-16 | 2018-01-03 | Shionogi & Co., Ltd. | Tricyclic heterocyclic derivative having hiv replication-inhibiting effect |
US9527864B2 (en) | 2014-09-15 | 2016-12-27 | Incyte Corporation | Tricyclic heterocycles as BET protein inhibitors |
TWI700284B (zh) * | 2015-05-29 | 2020-08-01 | 日商塩野義製藥股份有限公司 | 具有hiv複製抑制作用之含氮3環性衍生物 |
CN108349996B (zh) | 2015-09-08 | 2021-01-08 | 豪夫迈·罗氏有限公司 | 三环pi3k抑制剂化合物及其使用方法 |
AU2016324598A1 (en) | 2015-09-17 | 2018-03-15 | Marvin J. Miller | Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection |
TW201722966A (zh) | 2015-10-29 | 2017-07-01 | 英塞特公司 | Bet蛋白質抑制劑之非晶固體形式 |
FI3472157T3 (fi) | 2016-06-20 | 2023-06-01 | Incyte Corp | Bet-inhibiittorin kiteisiä kiinteitä muotoja |
HUE063811T2 (hu) | 2016-08-19 | 2024-02-28 | Gilead Sciences Inc | HIV-vírus-fertõzés megelõzõ vagy terápiás kezelésére alkalmas terápiás vegyületek |
KR102587510B1 (ko) | 2018-02-15 | 2023-10-11 | 길리애드 사이언시즈, 인코포레이티드 | 피리딘 유도체 및 hiv 감염을 치료하기 위한 그의 용도 |
WO2019161280A1 (en) | 2018-02-16 | 2019-08-22 | Gilead Sciences, Inc. | Methods and intermediates for preparing a therapeutic compound useful in the treatment of retroviridae viral infection |
WO2020006432A1 (en) | 2018-06-28 | 2020-01-02 | Eternity Bioscience Inc. | Fused tricyclic heterocycle compounds and therapeutic uses thereof |
CA3216031A1 (en) | 2018-07-16 | 2020-01-23 | Gilead Sciences, Inc. | Capsid inhibitors for the treatment of hiv |
US20220056044A1 (en) * | 2018-12-14 | 2022-02-24 | Jiangsu Hengrui Medicine Co., Ltd. | Tricyclic compounds as sting agonists, and preparation methods and medicinal uses thereof |
CN111471056B (zh) * | 2019-01-23 | 2021-07-02 | 成都先导药物开发股份有限公司 | 一种大环类免疫调节剂 |
CA3133070A1 (en) * | 2019-03-11 | 2020-09-17 | Collaborative Medicinal Development, Llc | Heteroaromatic and heterobicyclic aromatic derivatives for the treatment of ferroptosis-related disorders |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
CN116283758A (zh) * | 2023-03-30 | 2023-06-23 | 安徽工业大学 | 一种喹啉合成n-甲酰基四氢喹啉的方法及产品 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ECSP003637A (es) * | 1999-08-31 | 2002-03-25 | Agouron Pharma | Inhibidores triciclicos de poli (adp-ribosa) polimerasas |
KR20030020450A (ko) * | 2000-08-08 | 2003-03-08 | 사노피-신델라보 | 벤지미다졸 유도체, 그의 제조 방법 및 치료적 용도 |
EP1339402B1 (en) * | 2000-12-01 | 2010-08-25 | Eisai Inc. | Azaphenanthridone derivatives and their use as parp inhibitors |
-
2006
- 2006-07-21 US US11/996,727 patent/US20080318999A1/en not_active Abandoned
- 2006-07-21 EP EP06787957A patent/EP1912989A2/en not_active Withdrawn
- 2006-07-21 CA CA002616020A patent/CA2616020A1/en not_active Abandoned
- 2006-07-21 US US11/490,090 patent/US20070032469A1/en not_active Abandoned
- 2006-07-21 WO PCT/US2006/028165 patent/WO2007018998A2/en active Application Filing
- 2006-07-21 JP JP2008524995A patent/JP2009503069A/ja active Pending
- 2006-07-21 AU AU2006279034A patent/AU2006279034A1/en not_active Abandoned
- 2006-07-21 MX MX2008001152A patent/MX2008001152A/es not_active Application Discontinuation
- 2006-07-21 BR BRPI0614168A patent/BRPI0614168A2/pt not_active IP Right Cessation
- 2006-07-21 RU RU2008101923/04A patent/RU2008101923A/ru not_active Application Discontinuation
- 2006-07-21 CN CNA2006800344205A patent/CN101268077A/zh active Pending
- 2006-07-21 KR KR1020087001611A patent/KR20080035576A/ko not_active Application Discontinuation
- 2006-07-24 TW TW095126927A patent/TW200745112A/zh unknown
- 2006-07-28 UY UY29710A patent/UY29710A1/es not_active Application Discontinuation
- 2006-07-28 AR ARP060103273A patent/AR055100A1/es unknown
-
2008
- 2008-01-16 IL IL188809A patent/IL188809A0/en unknown
- 2008-01-22 EC EC2008008128A patent/ECSP088128A/es unknown
- 2008-01-25 NO NO20080475A patent/NO20080475L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU2006279034A1 (en) | 2007-02-15 |
IL188809A0 (en) | 2008-08-07 |
CN101268077A (zh) | 2008-09-17 |
KR20080035576A (ko) | 2008-04-23 |
NO20080475L (no) | 2008-04-15 |
WO2007018998A2 (en) | 2007-02-15 |
EP1912989A2 (en) | 2008-04-23 |
JP2009503069A (ja) | 2009-01-29 |
MX2008001152A (es) | 2008-04-02 |
US20070032469A1 (en) | 2007-02-08 |
ECSP088128A (es) | 2008-02-20 |
TW200745112A (en) | 2007-12-16 |
BRPI0614168A2 (pt) | 2017-07-25 |
AR055100A1 (es) | 2007-08-08 |
RU2008101923A (ru) | 2009-09-10 |
US20080318999A1 (en) | 2008-12-25 |
CA2616020A1 (en) | 2007-02-15 |
WO2007018998A3 (en) | 2007-05-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY29710A1 (es) | Benzimidazoles tricíclicos y su uso como moduladores de receptores metabotrópicos de glutamato | |
ECSP056134A (es) | Derivados de quinuclidina que se enlazan con los receptores muscarínicos m3 | |
UY30141A1 (es) | Nuevas isoindolonas potenciadoras de receptores metabotropicos de glutamato | |
ECSP088871A (es) | Derivados de triazolopirazina | |
UY28775A1 (es) | Tetrahidroquinolinonas y su uso como antagonistas de receptores de glutamato metabotropico | |
DE602006006712D1 (de) | Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren | |
SV2009003334A (es) | Moduladores receptores de niconítico de acetilcolina | |
UY29735A1 (es) | Piperazinas sustituidas como antagonistas de receptores de glutamato metabotrópicos | |
UY31127A1 (es) | Ligandos de oxiadazol del receptor metabotropico para el glutamato y su utilizacion como potenciadores - 841 | |
GT200500119A (es) | Derivados de tetraazabenzo [e] azuleno y sus analogos | |
CL2009000697A1 (es) | Compuestos derivados de 2-heteroaril-6-fenil-imidazol [1,2-a]piridinas sustituidas; moduladores de receptores not; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de cancer, inflamacion, enfermedades neurodegenerativas, psiquiatricas, epilepsia, entre otras. | |
CR8497A (es) | Derivados de azepinoindol como agentes farmaceuticos | |
GT200900283A (es) | "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario". | |
PE20090113A1 (es) | Compuestos triciclicos como moduladores del receptor de glucocorticoides, composiciones y procedimientos | |
CR8258A (es) | Derivados de azepine como agentes farmaceuticos | |
EA201490489A1 (ru) | Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7 | |
CR9910A (es) | Antagonistas del receptor 3 de la histamina | |
DOP2013000181A (es) | Moduladores del receptor de glucagon | |
CL2008002744A1 (es) | Compuestos derivados de 1,3-disustituidos-4-fenil-1h-piridin-2-ona, moduladores alostericos del receptor glutamatérgico mglur2; composición farmacéutica y uso de los compuestos en el tratamiento de afecciones neurológicas y siquiatricas mediadas por mglur2. | |
UY28839A1 (es) | Agentes terapeuticos | |
ECSP11011108A (es) | Piperidina espiro pirrolidinona y piperidinona sustituidas, su preparación y su uso terapéutico | |
ECSP10010168A (es) | Benzotiazolas como moduladores del receptor de ghrelina | |
ECSP088366A (es) | 1,2-diarilimidazoles para uso como moduladores de cb1 | |
CR10199A (es) | Derivados de benzimidazol | |
CL2008003927A1 (es) | Compuestos derivados de imidazo[1,2-a]piridina-2-heterociclil-metanona, moduladores de los receptores nucleares nurr1; compuestos intermediarios; composicion farmaceutica; medicamento; y uso para el tratamiento y prevencion de enfermedades neurodegenerativas, psiquiatricas, inflamatorias, osteoporosis, cancer, entre otras. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20160830 |